A new PG13-based packaging cell line for stable production of clinical-grade self-inactivating gamma-retroviral vectors using targeted integration.

Loew, R; Meyer, Y; Kuehlcke, K; Gama-Norton, L; Wirth, D; Hauser, H; Stein, S; Grez, M; Thornhill, S; Thrasher, A; Baum, C; Schambach, A

Loew, R; Meyer, Y; Kuehlcke, K; Gama-Norton, L; Wirth, D; Hauser, H; Stein, S; Grez, M; Thornhill, S; Thrasher, A; Baum, C; Schambach, A.

Affiliation

Loew R; EUFETS AG, Idar-Oberstein, Germany. Rainer.Loew@fresenius-biotech.com

Gene Ther ; 17(2): 272-80, 2010 Feb.

Article in En | MEDLINE | ID: mdl-19865181

Subject(s)

DNA Nucleotidyltransferases; Gene Transfer Techniques; Genetic Vectors; Retroviridae/genetics; Cell Line; Feasibility Studies; Gene Targeting; Genetic Therapy/methods; Granulomatous Disease, Chronic/therapy; Humans; Severe Combined Immunodeficiency/therapy

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Retroviridae / Gene Transfer Techniques / DNA Nucleotidyltransferases / Genetic Vectors Limits: Humans Language: En Journal: Gene Ther Journal subject: GENETICA MEDICA / TERAPEUTICA Year: 2010 Document type: Article Affiliation country: Germany Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google